JP2016525548A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525548A5
JP2016525548A5 JP2016529872A JP2016529872A JP2016525548A5 JP 2016525548 A5 JP2016525548 A5 JP 2016525548A5 JP 2016529872 A JP2016529872 A JP 2016529872A JP 2016529872 A JP2016529872 A JP 2016529872A JP 2016525548 A5 JP2016525548 A5 JP 2016525548A5
Authority
JP
Japan
Prior art keywords
combination
desmopressin
combination medicament
hours
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016529872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525548A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/047899 external-priority patent/WO2015013454A1/en
Publication of JP2016525548A publication Critical patent/JP2016525548A/ja
Publication of JP2016525548A5 publication Critical patent/JP2016525548A5/ja
Pending legal-status Critical Current

Links

JP2016529872A 2013-07-23 2014-07-23 Β−3アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物 Pending JP2016525548A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361857431P 2013-07-23 2013-07-23
US61/857,431 2013-07-23
PCT/US2014/047899 WO2015013454A1 (en) 2013-07-23 2014-07-23 Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020065913A Division JP7219736B2 (ja) 2013-07-23 2020-04-01 Β-3アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物

Publications (2)

Publication Number Publication Date
JP2016525548A JP2016525548A (ja) 2016-08-25
JP2016525548A5 true JP2016525548A5 (https=) 2017-08-31

Family

ID=51299056

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016529872A Pending JP2016525548A (ja) 2013-07-23 2014-07-23 Β−3アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物
JP2020065913A Active JP7219736B2 (ja) 2013-07-23 2020-04-01 Β-3アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020065913A Active JP7219736B2 (ja) 2013-07-23 2020-04-01 Β-3アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物

Country Status (11)

Country Link
US (2) US9814753B2 (https=)
EP (1) EP3024474B1 (https=)
JP (2) JP2016525548A (https=)
KR (3) KR20160033220A (https=)
CN (1) CN105579057A (https=)
AU (1) AU2014293141A1 (https=)
CA (1) CA2919198A1 (https=)
DK (1) DK3024474T3 (https=)
ES (1) ES2910361T3 (https=)
MX (1) MX2016001030A (https=)
WO (1) WO2015013454A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
RU2015144851A (ru) 2009-06-18 2019-01-10 Серенити Фармасьютикалз, Элэлси Безопасное применение десмопрессина
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9925232B2 (en) 2013-07-23 2018-03-27 Serenity Pharmaceuticals, Llc Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor
KR20160033220A (ko) 2013-07-23 2016-03-25 알러간, 인코포레이티드 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
ES2923438T3 (es) 2014-11-20 2022-09-27 Serenity Pharmaceuticals Llc Composiciones que comprenden bajas dosis de desmopresina en combinación con un antagonista del receptor alfaadrenérgico
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
WO2017210700A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
KR101877834B1 (ko) * 2017-04-27 2018-07-12 주식회사 다산제약 미라베그론의 신규한 염 및 이의 제조방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH495957A (de) 1966-09-15 1970-09-15 Ceskoslovenska Akademie Ved Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
IL101243A (en) 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
WO1999027905A1 (en) 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
ES2717656T3 (es) 2000-11-30 2019-06-24 Valeritas Inc Dispositivo con microsonda amovible sustancialmente libre sobre el alojamiento
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
JP3815496B2 (ja) * 2002-11-07 2006-08-30 アステラス製薬株式会社 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤
EP2322196A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
EP1706128B1 (en) 2003-12-08 2010-07-21 CPEX Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
DE102005016981A1 (de) 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
US20080261995A1 (en) 2005-12-21 2008-10-23 Pfizer Inc. Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor
JPWO2007083640A1 (ja) * 2006-01-18 2009-06-11 杏林製薬株式会社 頻尿及び尿失禁の予防又は治療剤
JP5451613B2 (ja) 2007-08-06 2014-03-26 アラーガン、インコーポレイテッド デスモプレシン薬物送達のための方法及びデバイス
CN101648017A (zh) 2008-08-12 2010-02-17 许洁 用于治疗泌尿生殖系统及下尿路疾病的联合药物组合物
EP2361092A4 (en) 2008-09-04 2012-07-11 Anthony I Rozmanith HEALTH CARE
WO2010075266A2 (en) 2008-12-22 2010-07-01 Serenity Pharmaceuticals Corporation Safe desmopressin administration
WO2010075327A1 (en) 2008-12-22 2010-07-01 Serenity Pharmaceuticals Corporation Desmopressin composition
RU2015144851A (ru) 2009-06-18 2019-01-10 Серенити Фармасьютикалз, Элэлси Безопасное применение десмопрессина
NZ599233A (en) * 2009-10-07 2013-04-26 Merck Sharp & Dohme Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US9522129B2 (en) * 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
EP2907504B1 (en) 2011-02-08 2017-06-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
RU2669565C2 (ru) 2012-03-19 2018-10-12 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
GB201312155D0 (en) 2013-07-05 2013-08-21 Ucl Business Plc Therapeutic invention
KR20160033220A (ko) 2013-07-23 2016-03-25 알러간, 인코포레이티드 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
US9925232B2 (en) 2013-07-23 2018-03-27 Serenity Pharmaceuticals, Llc Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor
AU2014315459A1 (en) 2013-09-03 2016-04-07 G2B Pharma Inc. Intranasal formulation for the treatment of cardiopulmonary resuscitation (CPR), cardiac life support (CLS), anaphylaxis and/or anaphylactoid reactions
ES2923438T3 (es) 2014-11-20 2022-09-27 Serenity Pharmaceuticals Llc Composiciones que comprenden bajas dosis de desmopresina en combinación con un antagonista del receptor alfaadrenérgico

Similar Documents

Publication Publication Date Title
JP2016525548A5 (https=)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2013121983A5 (https=)
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
JP2016185995A5 (https=)
JP2013541583A5 (https=)
JP2016539921A5 (https=)
RU2018136580A (ru) Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты
JP2013520448A5 (https=)
JP2019514990A5 (https=)
JP2016505050A5 (https=)
HRP20211488T1 (hr) Sastav i metoda za liječenje metaboličkih poremećaja
JP2014520874A5 (https=)
JP2020500930A5 (https=)
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
JP7369523B2 (ja) 中等度~重度のインフルエンザの処置
JP2016525147A5 (https=)
KR101896441B1 (ko) 국소투여형의 연하장애 개선용 의약품
JP2015515971A5 (https=)
JP2010526884A5 (https=)
JP2013542262A5 (https=)
JP2017513866A5 (https=)
JP2015533131A5 (https=)